Target General Infomation
Target ID
Target Name
COVID-19 spike glycoprotein (S)
COVID-19 S glycoprotein; COVID-19 E2; COVID-19 Peplomer protein
Gene Name
Target Status
Target in Phase 2 Trial
Disease [+] 1 Target-related Diseases +
1 COVID-19 [ICD-11: 1D6Y]
Mediates fusion of the virion and cellular membranes by acting as a class I viral fusion protein. Under the current model, the protein has at least three conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During viral and target cell membrane fusion, the coiled coil regions (heptad repeats) assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C-terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of viral and target cell membranes.
BioChemical Class
Betacoronaviruses spike protein family
UniProt ID
Drugs and Modes of Action
Drugs in Phase 2 Trial [+] 1 Drugs in Phase 2 Trial +
1 Nafamostat Drug Info Phase 2 Trial COVID-19 [2]
Investigative agents [+] 1 Investigative agents +
1 Toremifene Drug Info Investigative COVID-19 [3]
Mode of Action [+] 1 Modes of Action +
Inhibitor [+] 2 Inhibitor drugs +
1 Nafamostat Drug Info [1]
2 Toremifene Drug Info [3]
1 Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150.
2 (NCT04352400) Efficacy of Nafamostat in Covid-19 Patients (RACONA Study). U.S. National Institutes of Health.
3 Repurposing of FDA-Approved Toremifene to Treat COVID-19 by Blocking the Spike Glycoprotein and NSP14 of SARS-CoV-2. June 5, 2020.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.